Moderna mRNA-1574 mRNA-1644 HIV Vaccines 2022
Moderna Inc.'s HIV vaccine candidate mRNA-1644 is conducting a Phase 1 clinical study, the first study in a series of planned iterative clinical trials with the primary aim to validate a novel vaccination approach, i.e., to elicit specific broadly neutralizing antibodies against HIV using an antigen guided antibody germline targeting. mRNA-1644 collaborates with the International AIDS Vaccine Initiative (IAVI) and the Bill & Melinda Gates Foundation.
A second HIV vaccine candidate, mRNA-1574, is being evaluated with IAVI, SCRIPPS, and the National Institutes of Health (NIH) to test and compare multiple native-like HIV env trimer antigens. mRNA-1574 HIV vaccine is also based on Moderna's mRNA platform. This vaccine will utilize multiple mRNAs encoded native-like HIV trimers to induce sustained protective levels of HIV neutralizing antibodies.
The envelope trimers were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center.
“Finding an HIV vaccine has proven a daunting scientific challenge,” said Anthony S. Fauci, M.D. NIAID director, in March 2022. “With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to learn whether mRNA technology can achieve similar results against HIV infection.”
Massachusetts-based Moderna says, 'Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.'
mRNA-1574 mRNA-1644 HIV Vaccine News
May 4, 2022 - Moderna Inc. confirmed the Phase 1 study of mRNA-1574 is ongoing.
March 14, 2022 - Moderna announced they have begun their Phase 1 clinical trial of its HIV Trimer mRNA vaccine candidate.
mRNA-1574 mRNA-1644 HIV Vaccine Clinical Trials
Moderna has dosed their first participant in the Phase 1 clinical trial. Clinical Trial NCT05217641: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants. This trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults aged 18 to 55 years.